Elevation Oncology, which spent the spring fending off activist investor demands to wind down, has become the latest ...

After nearly 25 years with Sanofi, Sanjay Gurunathan, M.D., has left for GSK, where he will lead vaccine and infectious ...

Merck & Co.’s ambition to get the first oral PCSK9 inhibitor to market came one step closer this morning as the pharma ...

NewAmsterdam Pharma’s push to show a cholesterol drug can prevent Alzheimer’s disease has passed another test. | NewAmsterdam ...

Dietmar Berger, M.D., Ph.D., joined Gilead Sciences as chief medical of | Dietmar Berger became Gilead Sciences’ new chief ...

Global trade uncertainty and evolving tariff policies are shifting how bioscience companies view their supply chains.   | ...

Metsera has linked its amylin analog to 8.4% placebo-adjusted weight loss at Day 36, advancing its push to develop an ...

A new paper published in Nature on June 4 shines light on how an enigmatic part of male aging—the loss of Y chromosomes—is ...

TegMine has identified Taiwan’s OBI as a company that can help advance its ambitions. The new deal secures TegMine the right ...

Protara, hoping to ultimately transition to a commercial stage company, snagged a chief commercial officer in Bill Conkling, ...

Sibeprenlimab targets a protein called A proliferation-inducing ligand (APRIL), and the drug is designed to limit the ...

As favor in the general market swings away from cell therapy, Immatics’ CEO is choosing to focus on what he can control: ...